Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 25Terminated 6Unknown 5Withdrawn 3Recruiting 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 7Gastrointestinal Stromal Tumors 5Urologic Neoplasms 2Prostatic Neoplasms 2Neoplasm Metastasis 2Multiple Myeloma 2Lymphoma 2Carcinoma 2Uveal Melanoma 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Thymoma 1Stomach Neoplasms 1Sarcoma 1Rectal Neoplasms 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Neoplasms by Site 1Neoplasms 1Melanoma 1Lung Neoplasms 1Kidney Neoplasms 1Kidney Diseases 1Hematologic Neoplasms 1Glioma 1Esophageal Neoplasms 1Endometrial Neoplasms 1Colorectal Neoplasms 1

Interventions

Nivolumab 8belzutifan 7pembrolizumab 6Ipilimumab 5cabozantinib 3Surveys and Questionnaires 3lenvatinib 2Radiosurgery 2Paclitaxel 2Everolimus 2Carboplatin 2pazopanib 1palbociclib 1liposomal doxorubicin 1guadecitabine 1fludarabine phosphate 1endothelial PAS domain-containing protein 1 1durvalumab 1cemiplimab 1atezolizumab 1aldesleukin 1X-Rays 1Technetium Tc 99m Sestamibi 1Taxes 1Sunitinib 1Spermine Synthase 1Social Determinants of Health 1Single Photon Emission Computed Tomography Computed Tomography 1Radiotherapy 1Radionuclide Imaging 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Kidney Neoplasms × Sunitinib × Clear all
NCT03091192 2026-04-14

Savolitinib vs. Sunitinib in MET-driven PRCC.

AstraZeneca

Phase 3 Active not recruiting
60 enrolled 15 charts
Genitourinary

Carcinoma, Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms by Site, Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡